Enrolment has begun in the first of two multinational clinical trials of an intravenously delivered investigational antibody for preventing HIV infection.
Known as the AMP Studies, for antibodymediated prevention, the trials will test whether giving people an investigational anti-HIV antibody called VRC01 as an intravenous infusion every eight weeks is safe, tolerable and effective at preventing HIV infection. With a projected enrollment of 4,200 adults, the trials are also designed to answer scientific questions for the fields of HIV prevention and vaccine research.
